Oncology Biosimilars Global Market Report 2025

Description

Oncology biosimilars are medications designed to closely resemble biologic cancer treatments, providing comparable physiological effects. A common side effect of cancer therapy is decreased white blood cell counts, which can elevate the risk of infections.

Within oncology biosimilars, key drug types include monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators primarily target pathways involved in treating multiple myeloma and several other cancers. These treatments are utilized for various cancer types such as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer. They are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2024 to $8.85 billion in 2025 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars.

The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $16.48 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence.

The expiration of patents on biologics utilized in cancer treatment is spurring the development of new oncology biosimilars. Biologics, derived from living organisms, have a limited patent lifespan, creating opportunities for the emergence of biosimilars similar but not identical alternatives to biologics that offer comparable effectiveness at reduced costs. Nearly 20 patents for oncology biologics are set to expire by 2023, prompting the production of new oncology biosimilars. This increased patent expiration rate is anticipated to drive demand for these biosimilars, fueling growth in the oncology biosimilars market.

Government initiatives aimed at combating cancer are poised to propel growth in the oncology biosimilars market. These initiatives denote actions or policies introduced by government bodies at various levels to address specific issues or achieve particular objectives. Efforts to reduce cancer rates create an environment conducive to the development and adoption of oncology biosimilars. For instance, in 2022, President Biden announced the revitalization of the Cancer Moonshot, setting new goals to halve the cancer death rate within 25 years and enhance the lives of cancer patients and survivors. This initiative marshals federal resources to accelerate cancer research, fostering improved prevention methods. Hence, government-led endeavors to combat cancer stimulate the oncology biosimilars market.

Pharmaceutical companies are increasingly allocating resources to research and development for the production of new oncology biosimilars. These companies are capitalizing on the growth potential of the expanding biosimilar market by enhancing their R&D processes to support the research and production of innovative biosimilars. For example, in May 2022, Biocon Biologics, a biopharmaceutical company based in India, and Viatris Inc., a US-based manufacturer of biosimilars, launched Abevmy (bevacizumab) in Canada, marking their third oncology biosimilar. Abevmy is a biosimilar of Roche's Avastin (bevacizumab), a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). By inhibiting VEGF, Abevmy plays a crucial role in preventing the formation of new blood vessels that tumors require for growth.

Major players in the oncology biosimilars sector are directing investments toward cancer drugs to combat the disease. Their investments serve as a critical link between top-tier cancer care and sustainable healthcare solutions. For example, in March 2023, Pfizer, in a merger with Seagen, invested $43 billion to combat cancer. This move enhances Pfizer's presence in the oncology field, contributing significantly to the fight against cancer, a primary global cause of mortality.

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

North America was the largest region in the global oncology biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oncology biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Other Cancer Types
3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Monoclonal Antibody: Rituximab Biosimilars; Trastuzumab Biosimilars; Bevacizumab Biosimilars; Pembrolizumab Biosimilars
2) By Immunomodulators: Thalidomide Biosimilars; Lenalidomide Biosimilars; Pomalidomide Biosimilars
3) By Hematopoietic Agents: Epoetin Biosimilars; Darbepoetin Biosimilars
4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars; Pegfilgrastim Biosimilars
Companies Mentioned: Biocon Biologics Limited; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32943

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Trends And Strategies

4. Oncology Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Oncology Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Oncology Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oncology Biosimilars Market Growth Rate Analysis
5.4. Global Oncology Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oncology Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oncology Biosimilars Total Addressable Market (TAM)

6. Oncology Biosimilars Market Segmentation

6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody
Immunomodulators
Hematopoietic Agents
Granulocyte Colony-Stimulating Factor (G-CSF)
6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Colorectal Cancer
Blood Cancer
Neutropenia Cancer
Non-Small Cell Lung Cancer
Other Cancer Types
6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rituximab Biosimilars
Trastuzumab Biosimilars
Bevacizumab Biosimilars
Pembrolizumab Biosimilars
6.5. Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Thalidomide Biosimilars
Lenalidomide Biosimilars
Pomalidomide Biosimilars
6.6. Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epoetin Biosimilars
Darbepoetin Biosimilars
6.7. Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Filgrastim Biosimilars
Pegfilgrastim Biosimilars

7. Oncology Biosimilars Market Regional And Country Analysis

7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Biosimilars Market

8.1. Asia-Pacific Oncology Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Biosimilars Market

9.1. China Oncology Biosimilars Market Overview
9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Biosimilars Market

10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Biosimilars Market

11.1. Japan Oncology Biosimilars Market Overview
11.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Biosimilars Market

12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Biosimilars Market

13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Biosimilars Market

14.1. South Korea Oncology Biosimilars Market Overview
14.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Biosimilars Market

15.1. Western Europe Oncology Biosimilars Market Overview
15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Biosimilars Market

16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Biosimilars Market

17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Biosimilars Market

18.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Biosimilars Market

19.1. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Biosimilars Market

20.1. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Biosimilars Market

21.1. Eastern Europe Oncology Biosimilars Market Overview
21.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Biosimilars Market

22.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Biosimilars Market

23.1. North America Oncology Biosimilars Market Overview
23.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Biosimilars Market

24.1. USA Oncology Biosimilars Market Overview
24.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Biosimilars Market

25.1. Canada Oncology Biosimilars Market Overview
25.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Biosimilars Market

26.1. South America Oncology Biosimilars Market Overview
26.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Biosimilars Market

27.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Biosimilars Market

28.1. Middle East Oncology Biosimilars Market Overview
28.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Biosimilars Market

29.1. Africa Oncology Biosimilars Market Overview
29.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Biosimilars Market Competitive Landscape And Company Profiles

30.1. Oncology Biosimilars Market Competitive Landscape
30.2. Oncology Biosimilars Market Company Profiles
- 30.2.1. Biocon Biologics Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. STADA Arzneimittel AG Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Biosimilars Market Other Major And Innovative Companies

31.1. Pfizer Inc.
31.2. Apotex Inc.
31.3. Teva Pharmaceutical Industries Ltd.
31.4. Sandoz International GmbH
31.5. BIOCAD
31.6. Amgen Inc.
31.7. F. Hoffmann-La Roche
31.8. Baxter International Inc.
31.9. Sanofi SA
31.10. Mylan
31.11. Samsung Bioepis
31.12. Biogen International GmbH
31.13. Merck & Co. Inc.
31.14. Coherus Biosciences
31.15. Eli Lilly and Company

32. Global Oncology Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Biosimilars Market

34. Recent Developments In The Oncology Biosimilars Market

35. Oncology Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Oncology Biosimilars Market In 2029 - Countries Offering Most New Opportunities
35.2 Oncology Biosimilars Market In 2029 - Segments Offering Most New Opportunities
35.3 Oncology Biosimilars Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer